1. Home
  2. GAME vs MDXH Comparison

GAME vs MDXH Comparison

Compare GAME & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GameSquare Holdings Inc.

GAME

GameSquare Holdings Inc.

HOLD

Current Price

$0.44

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.55

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAME
MDXH
Founded
2011
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
41.1M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
GAME
MDXH
Price
$0.44
$0.55
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
1.4M
729.1K
Earning Date
04-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
65.14
N/A
EPS
N/A
N/A
Revenue
$44,999,302.00
N/A
Revenue This Year
$87.12
$30.78
Revenue Next Year
$21.14
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.51
52 Week High
$2.87
$5.33

Technical Indicators

Market Signals
Indicator
GAME
MDXH
Relative Strength Index (RSI) 51.87 20.90
Support Level $0.44 $0.51
Resistance Level $0.49 $3.79
Average True Range (ATR) 0.04 0.07
MACD 0.00 0.05
Stochastic Oscillator 51.74 12.62

Price Performance

Historical Comparison
GAME
MDXH

About GAME GameSquare Holdings Inc.

GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: